Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347380 | 0.79 | GLA (0.38) | GLAHSD11B1CHRM1LMNANPSR1 | |
| SCHEMBL2445606 | 0.76 | NPSR1 (0.46) | HSD11B1CHRM1LMNANPSR1 | |
| SCHEMBL22347196 | 0.74 | GLA (0.38) | GLAHSD11B1CHRM1LMNA | |
| SCHEMBL1679811 | 0.72 | HSD11B1 (0.39) | HSD11B1CHRM1LMNANPSR1 | |
| SCHEMBL1305982 | 0.71 | DGAT1 (0.40) | HSD11B1CHRM1LMNANPSR1 | |
| SCHEMBL2451039 | 0.69 | NPSR1 (0.46) | GLAHSD11B1CHRM1LMNANPSR1 | |
| SCHEMBL6635776 | 0.68 | L3MBTL1 (0.46) | GLALMNANPSR1 | |
| SCHEMBL19271800 | 0.68 | NPSR1 (0.40) | HSD11B1CHRM1LMNANPSR1 | |
| SCHEMBL12302197 | 0.68 | NPSR1 (0.40) | HSD11B1CHRM1LMNANPSR1 | |
| SCHEMBL705019 | 0.68 | NPSR1 (0.40) | HSD11B1CHRM1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-02-18 | — | — | US | disclosed |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-06 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| EP-3924337-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168148-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020168152-A2 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227496-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | GLA 2954/4885HSD11B1 96/4885CHRM1 497/4885 |
| US-20230109670-A9 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | GLA 2954/4885HSD11B1 96/4885CHRM1 497/4885 |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | GLA 2613/4885HSD11B1 83/4885CHRM1 181/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | GLA 2954/4885HSD11B1 96/4885CHRM1 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.